J Breast Cancer.
2020 Apr;23(2):230-231. 10.4048/jbc.2020.23.e19.
Erratum: Analysis of Tau Protein Expression in Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Different Molecular Subtypes of Breast Cancer
- Lei C
1,2 - Yang C1
- Xia B3,4
- Ji F1
- Zhang Y1
- Gao H1
- Xiong Q5
- Lin Y6
- Zhuang X1,7
- Zhang L1
- Zhu T1
- Cheng M1
- Yang M1
- Wang K1,2
- Affiliations
-
- 1Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
- 2The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China
- 3Clinical Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China
- 4Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China
- 5Department of General Surgery, Shenzhen Tradition Chinese Medicine Hospital, Shenzhen, China
- 6Department of General Surgery, Zhuhai Golden Bay Center Hospital, Zhuhai, China
- 7Shantou University Medical College, Shantou, China
- KMID: 2500159
- DOI: http://doi.org/10.4048/jbc.2020.23.e19
Abstract
- This corrects the article “Analysis of Tau Protein Expression in Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Different Molecular Subtypes of Breast Cancer” in volume 23 on page 47. This article was initially published on the Journal of Breast Cancer with a misspelled the abbreviation in figure 3. The abbreviation ‘HP’ should be corrected as ‘HR’.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Analysis of Tau Protein Expression in Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Different Molecular Subtypes of Breast Cancer
- Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy
- Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
- The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Non–Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors
- Comment on “Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancerâ€
